Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631801 | 0.86 | CYP3A4 (0.48) | AURKARPS6KB1AURKBPRKCQCYP2C9 | |
| SCHEMBL1673902 | 0.82 | GPR119 (0.60) | ALDH1A1MAPTKMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL12806630 | 0.82 | AURKA (0.45) | AURKARPS6KB1AURKBEGFRLMNA | |
| SCHEMBL1673949 | 0.82 | HTT (0.48) | AURKARPS6KB1AURKBEGFRHTT | |
| SCHEMBL27652097 | 0.81 | ATM (0.42) | RPS6KB1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1673601 | 0.80 | AURKA (0.51) | AURKARPS6KB1EGFRHTTCA1 | |
| SCHEMBL12733780 | 0.76 | HTT (0.63) | HTTCA1CA2CA7CA13 | |
| SCHEMBL12733773 | 0.75 | HTT (0.47) | AURKARPS6KB1EGFRPRKCQHTT | |
| SCHEMBL14421375 | 0.70 | HTT (0.62) | RPS6KB1HTTLMNAALDH1A1CNR1 | |
| SCHEMBL1673759 | 0.69 | GPR119 (0.62) | ALDH1A1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| EP-1927594-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | Arena Pharmaceuticals, Inc. (US) | 2008-06-04 | — | — | EP | claimed |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | claimed |
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933083-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8293751-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1927594-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | Arena Pharmaceuticals, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1599468-B1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARM INC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | ARENA PHARMACEUTICALS | 2006-09-28 | — | — | US | disclosed |
| CN-1835943-A | 1,2, 3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of diseases related thereto, such as diabetes and hyperglycemia | ARENA PHARM INC (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1599468-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004065380-A1 | 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA | ARENA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023527-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | AURKA 4730/4885RPS6KB1 1794/4885AURKB 4187/4885 |
| US-20110082134-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | CYP7A1, GPR119, UGT1A1 | AURKA 4730/4885RPS6KB1 1794/4885AURKB 4187/4885 |
| US-20060217379-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | UGT1A1, GPR119, UGT1A3 | AURKA 4714/4885RPS6KB1 3725/4885AURKB 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.